secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-05-15T20:08:23+00:00
Accession:  0001193125-26-226691
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart
--------------------------------------------------------------------------------

- Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
- Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.
- CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.
- Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.
- Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-226691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer